Background: The objective of this study was to evaluate the age-based enrolment of cancer patients into registration trials of new drug applications or expanding the indications for use.
introduction
Cancer is a disease of the elderly, with 60% of patients aged 65 years or more [1] . The elderly population in Japan has considerably increased when compared with the numbers in the other countries [2] . Twenty-two percent of the Japanese population was aged 65 years or more in 2008, and approximately 41% of the Japanese population will be aged 65 years or more by 2055.
Many studies reported that elderly cancer patients are generally underrepresented in cancer clinical trials [3, 4] . Previous studies by clinical trial groups (i.e. SWOG, NCI, NCIC CTG) reported the overall population of patients aged 65 years or more in clinical trials were 25%, 32%, 22%, whereas corresponding numbers in the cancer population of these countries were 63%, 61%, 58%, respectively [5] [6] [7] . In oncology registration trial, the United States (US) Food and Drug Administration (FDA) reported that the overall proportion of patients aged 65 years or more enrolled in the registration trials was 36%, whereas the corresponding number for the US cancer population was 60% [8] , which is slightly higher than that reported in studies by clinical trial groups.
The Pharmaceuticals and Medical Devices Agency (PMDA) is a Japanese regulatory agency working in conjunction with the Ministry of Health, Labour and Welfare (MHLW) [9] . The major roles of the PMDA are to conduct drug and medical device reviews, evaluate postmarketing safety, and provide relief services with regard to adverse effects of drugs. The PMDA conducts scientific reviews of marketing authorization applications for pharmaceuticals and medical devices and also clinical trial consultations. On the basis of these reviews, the MHLW approves new drug applications (NDAs) or extension of indications (EI) for Japan. The PMDA has also analyzed the median age of patients enrolled in 68 registration trials of NDA or EI approved in Japan from 1999 to 2005 [10] . This study also reported that the median age of patients enrolled in the registration trial conducted in Japan was lower than that of the Japanese cancer population, but the proportion of patients aged 65 years or more was not investigated. In this study, we evaluated elderly cancer patient enrollment of registration trials for the application of NDA or EI approved in Japan between 1999 and 2008. For each type of cancer, drug, and application, the estimated median age of the patients enrolled in registration trials conducted in Japan were respectively compared with those conducted in countries other than Japan as well as the Japanese cancer population overall. Similarly, the rate of enrollment of patients aged 65 years or more was compared with the corresponding rates in overseas trials and the Japanese cancer population.
materials and methods registration trial data sources
Data from patients enrolled in registration trials, which included trials conducted in Japan and overseas, for NDA or EI of oncology drugs, or drugs for supportive care of cancer, reviewed by the PMDA between 1999 and 2008, were extracted from the review reports of the PMDA and the documents submitted by the application sponsors, which have been publicly released on the websites of the PMDA and the Japan Pharmacists Education Center [11, 12] . This study excluded data from phase I oncology registration trials because these trials generally included patients with any type of cancer. Global registration trials including patients in Japan and overseas were also excluded. For each registration trial, data with respect to the type of cancer, drug, treatment, application, region, median age of patients enrolled in the registration trial, and percentage of patients aged 65 years or more were collected.
age distributions of Japanese and US cancer populations
For each type of cancer and all cancers combined, the median age and the proportion of patients aged 65 years or more in the Japanese cancer population were estimated as follows. We obtained the age-specific incidence from Cancer Statistics in Japan 2003 [13] , and the population by age group from the Annual Report on MHLW 2003-2004 [14] , and multiplied them to estimate the number of age-specific, newly diagnosed cancer patients. The median age and the proportion of patients aged 65 years or more were calculated on the basis of the number and ages of newly diagnosed cancer patients. For each type of cancer and all cancers combined, the median age and the proportion of patients aged 65 years or more in the US cancer population, from the Surveillance, Epidemiology, and End Results Program for the period 2002-2006 and released by the National Cancer Institute, were used as a reference for the age distribution of patients enrolled in overseas registration trials [15] .
comparisons of age distribution between registration trials and general cancer populations For each type of cancer and all cancers combined, we calculated the average median age and the average proportion of patients aged 65 years or more enrolled in registration trials conducted in Japan, and we compared that data with the data from trials conducted overseas and Japanese and US cancer populations. Comparisons were also made for each type of drug, treatment, or application.
results registration trials
An overview of the 234 registration trials of 43 drugs (32 NDA and 11 EI) analyzed in this study is given in Table 1 . The trials were conducted on 19 cytotoxic drugs, 6 small molecular target drugs, 5 hormonal drugs, 4 antibody drugs, 3 supportive care drugs, and 6 miscellaneous drugs. Table 2 shows the estimated median age of patients in Japanese and US cancer populations and the distribution of the median age of patients in registration trials for each type of cancer and all cancers combined. The average median age of cancer patients in the 234 registration trials was 59 years, whereas it was 55 years in the registration trials conducted overseas and 70 years in the Japanese cancer population. For each type of cancer except for uterine cancer, the average median age of patients in the registration trials was lower than the estimated median age of the Japanese cancer population but was similar to that in the case of the overseas registration trials. It should be noted that the difference in the median age between the registration trials and the Japanese cancer population was smaller in patients with breast and prostate cancer than in those with other solid cancers. On the other hand, the average median age of patients enrolled in registration trials for hematologic malignancies was more than 10 years lower than the estimated median age of the Japanese cancer population. Additionally, for each cancer and all cancers combined, with the exception of liver and prostate cancer, the average median age of patients in registration trials conducted overseas was lower than the estimated median age of the US cancer population. Table 3 shows the distribution of median age for each type of drug and application in Japan and overseas. In Japan and overseas, the average median age was approximately 60 years for all types of drugs except for supportive care drugs. The average median age in NDA trials was higher than that in those studying EI by approximately 5 years.
comparison of median age
comparison of the proportion of patients aged 65 years or more Of the 234 registration trials, the 66 registration trials were available to obtain the data pertaining to the proportion of patients aged 65 years or more from the data sources. Table 4 shows the estimated proportion of patients aged 65 years or more in Japanese and US cancer populations and the For each type of cancer except for uterine cancer, the average proportion of patients aged 65 years or more in registration trials was lower than the estimated proportion of patients aged 65 years or more in the Japanese cancer population, although the number of trials was small. In Japan and overseas, the average proportion of patients aged 65 years or more in registration trials for prostate cancer was more than 80%. The average proportion of patients aged 65 years or more in registration trials conducted in Japan was similar to that of the trails conducted overseas for lung cancer, gastric cancer, kidney cancer, breast cancer, prostate cancer, and lymphoma. Table 5 shows the distribution of the proportion of patients aged 65 years or more for each type of drug and application in Japan and overseas. The average proportions of patients aged 65 years or more in registration trials conducted in Japan for cytotoxic, molecular target, and hormonal drugs were the same. Additionally, the average proportion of patients aged 65 years or more in registration trials conducted in Japan for NDA was higher than that in the trials conducted to study EI. These trends were also observed in registration trials conducted overseas.
discussion
The present study indicated that the estimated median age of patients and the proportion of patients aged 65 years or more in the registration trials conducted in Japan were almost the same as those in overseas trials for each type of cancer and all cancers combined, but was lower than the estimated values of the Japanese cancer population. The proportion of patients aged 65 years or more in the registration trials conducted in Japan was similar to that reported in studies by clinical trial groups and FDA (35% versus 25%, 32%, 22%, and 36%) [5] [6] [7] [8] . Our study confirmed that elderly patients were underrepresented in the registration trials and that this is a significant problem observed worldwide.
Registration trials for NDA or EI are generally conducted in patients of all ages, and their results are reviewed by the relevant regulatory agency in order to evaluate the generalizability of efficacy and safety for the general cancer population. Evidence based on the results of registration trials with lower enrollment of elderly patients may not be entirely suitable for elderly cancer patients. Effective strategies are needed to include an adequate number of elderly patients in registration trials and to conduct specific clinical trials in order to evaluate the risks and benefits of cancer therapies in them [7, 16] . The following approaches may be useful in motivating pharmaceutical companies and investigators to conduct registration trials or postmarketing studies for elderly patients: (i) prioritizing a review if the application includes data from a registration trial conducted specifically for elderly patients, (ii) making it mandatory for pharmaceutical companies to conduct postmarketing studies if subgroup analyses reveal differential toxicity profiles or safety risks for elderly patients, and (iii) establishing a research grant to encourage clinical trial groups to conduct postmarketing studies that include elderly patients.
Similarly, the underrepresentation of elderly patients in Japan and other countries may be attributed to the following barriers [3, 4, 17] : (i) trial-design barriers whereby elderly patients do not meet the eligibility requirements because of comorbidities or deteriorating organ or psychological function; Japan  44  60  1  2  0  0  8  6  13  11  3  Overseas  55  60  1  0  1  1  8  10  25  7  2  Molecular  target   Japan  7  59  0  0  0  0  0  4  3  0  0  Overseas  29  58  0  0  2  2  2  8  13  2  0  Antibody  Japan  4  58  0  0  0  0  0  3  1  0  0  Overseas  39  58  0  0  0  3  5  17  10 
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(ii) physicians tending to have a negative bias against the enrollment of elderly patients; and (iii) patient factors including a desire to choose their own treatment, distance from the treatment institution, and socioeconomic factors. Most elderly patients are willing to consider participation in cancer clinical trials, but they do not appear to actively seek out clinical trials and few seem to be informed of the availability of clinical trials [18] . In addition to the abovementioned barriers, the present study showed that both Japanese and overseas researchers may tend to enroll a higher number of elderly patients in trials for treatments with lower toxicity than in those for treatments with higher toxicity. For breast and prostate cancers, the differences in the estimated median age of patients and the proportion of patients aged 65 years or more between the registration trials and general cancer populations in Japan and overseas were relatively small, probably because the registration trials for evaluating hormonal drugs for these cancers, which are comparatively less toxic, included more elderly patients than the registration trials for the other cancers [7] . In Japan and overseas, the estimated median age of patients and the proportion of patients aged 65 years or more in registration trials for hematologic malignancies were lower than those in the registration trials for solid cancers. Investigators may hesitate to enroll elderly patient with hematologic malignancies since these [7, [19] [20] [21] .
There are some particular barriers in Japan, which differ from those observed overseas. Because of cultural barriers, the implications and necessity of clinical trials are not known to a majority of the Japanese population [22] . Additionally, in Japan, more elderly people live in provinces than in major metropolitan areas [23] and may not have much opportunity to participate in clinical trials as compared with patients living in major metropolitan areas containing most institutions that conduct clinical trials. Elderly patients may not be motivated enough to participate in clinical trials because their medical expenses are quite low owing to the subsidy offered by the national medical insurance system [24] . Additionally, past experiences such as infection caused by the use of HIV-or hepatitis C-contaminated blood products may dissuade elderly patients from enrolling in clinical trials [25, 26] . Furthermore, since the PMDA had not made it mandatory to conduct a phase III trial for NDAs or EIs in oncology until 2006 [27] , single-arm phase I/II or II trials with a small sample size were frequently conducted, and researchers might avoid enrolling elderly patients in such trials.
Effective measures against these barriers would include conducting educational exhibits and making announcements via mass media in order to increase the awareness of the importance of clinical trials among the general and elderly population. It is important that 'industrial, government, and academia' emphasize the implications and necessity of clinical trials for the elderly patients.
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